Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease.
about
Continued efforts to translate diabetes cardiovascular outcome trials into clinical practiceRecent advances in managing and understanding diabetic nephropathyManagement of diabetes mellitus in individuals with chronic kidney disease: therapeutic perspectives and glycemic controlDiabetic nephropathy - Epidemiology in Asia and the current state of treatmentThiazolidinedione use is associated with better survival in hemodialysis patients with non-insulin dependent diabetes.Semantic MEDLINE for discovery browsing: using semantic predications and the literature-based discovery paradigm to elucidate a mechanism for the obesity paradox.Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study.Thiazolidinediones and Risk of Long-Term Dialysis in Diabetic Patients with Advanced Chronic Kidney Disease: A Nationwide Cohort Study.Comparison of the Effects of Pioglitazone versus Placebo when Given in Addition to Standard Insulin Treatment in Patients with Type 2 Diabetes Mellitus Requiring Hemodialysis: Results from the PIOren Study.Exploring metabolic dysfunction in chronic kidney disease.Renal Outcomes of Pioglitazone Compared with Acarbose in Diabetic Patients: A Randomized Controlled Study.Limitations and future treatment options in type 2 diabetes with renal impairment.Glucose-lowering therapy in type 2 diabetes. New hope after the EMPA-REG outcome trialAdipokines protecting CKD.Kidney transplant in diabetic patients: modalities, indications and resultsAMP-activated protein kinase pathway: a potential therapeutic target in cardiometabolic disease.The association of pioglitazone and urinary tract disease in type 2 diabetic Taiwanese: bladder cancer and chronic kidney diseaseIn vivo actions of peroxisome proliferator-activated receptors: glycemic control, insulin sensitivity, and insulin secretion.Do we still need pioglitazone for the treatment of type 2 diabetes? A risk-benefit critique in 2013.Nutrition and IBD: Malnutrition and/or Sarcopenia? A Practical Guide.Role of altered insulin signaling pathways in the pathogenesis of podocyte malfunction and microalbuminuria.Pioglitazone: beyond glucose control.Thiazolidinediones and cardiovascular risk - a question of balance.Current and emerging antiglycaemic pharmacological therapies: the renal perspective.The renoprotective actions of peroxisome proliferator-activated receptors agonists in diabetes.Use of dipeptidyl peptidase-4 inhibitors for the treatment of patients with type 2 diabetes mellitus and chronic kidney disease.Achieving glycemic control in patients with type 2 diabetes and renal impairment.Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease.Diabetic nephropathy: landmark clinical trials and tribulations.Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.Comparative RNA-Seq transcriptome analyses reveal distinct metabolic pathways in diabetic nerve and kidney disease.Diabetes Mellitus Following Renal Transplantation: Clinical and Pharmacological Considerations for the Elderly Patient.Dual PPAR α / γ Agonism Normalizes Lipoprotein Profile of Renal Dyslipidemia.Endothelial factors and diabetic nephropathy.Secular trends in antihyperglycaemic medication prescriptions in older adults with diabetes and chronic kidney disease: 2004-2013.Moderate- to high-intensity statins for secondary prevention in patients with type 2 diabetes mellitus on dialysis after acute myocardial infarction.Nervous System Expression of PPARγ and Mutant PPARγ Has Profound Effects on Metabolic Regulation and Brain Development.Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG).Glycemic and lipidic profile in diabetic patients undergoing dialysis.Nephro- and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial.
P2860
Q26741860-E29DA687-00CE-4DA3-A315-C5F8342B10BEQ26745900-85F0B675-0377-4ACB-908C-A84962664C97Q26766259-36AC5DC4-351F-4B28-AC23-C8C590F931B6Q28742785-D444AA7B-DE7A-4044-B54C-808256BC233EQ33827960-4BECA82A-2757-4747-9915-F5C8F566DFD6Q35097849-BEDE1046-D06A-4CB2-BE4D-35D3E0BFEB3EQ35189566-1778DAA1-14C9-408B-992D-F4AEBE39E3E4Q35665975-5C6AA25C-45B2-4412-8E92-6C5322ED5F0FQ36058654-C4233197-4923-4450-A065-D4C8C6DE8E2AQ36123347-18BB6331-7C06-4ED3-9C4B-AA1500A79E36Q36182173-453C70D8-DE50-471B-AEB8-420AE35EEE27Q36783886-F4E92096-CE3A-4414-BB9B-770D2E8AF3D1Q36820255-8BC157AE-0B2E-461F-98B7-10B083A9B9FDQ37270838-E03A3D4F-606C-4D1A-9DF8-1B08AA1E64CDQ37379151-56E8A0CC-4074-4554-8510-778825243626Q37411713-F40004A5-CC71-4378-AEED-93BB6BA3DC06Q37464712-3A611D92-D749-469A-829D-E121978F31E0Q37577126-BA86779E-FD57-4688-9A65-1448A6D007B1Q37577159-5BC2561D-773B-4165-A795-4F114DBBB8FDQ37588746-A3247B34-4DF1-44E1-9049-C18C9825359EQ37590634-0EDBFA7E-1F32-454B-8679-C272827F0CE8Q37776510-DE482D1E-82C2-4F29-B8E1-8B5C7F89BD5AQ37777027-1CFCA6E7-6747-460B-BEE9-3C0564EFA2A5Q37860396-CE1BCA7F-F7D8-4597-8F31-D8CF7C8BC033Q37997004-3702DDE5-5B41-4F4C-9A67-18B1BBE727F6Q38036778-1F2DACA7-CED0-454C-BDA3-3734B1CE90CBQ38065109-4CBE542F-E92D-4942-8516-51137CA99F59Q38086611-F44457A7-C1E1-45F5-9D0B-E178D6BBE4A8Q38338539-C65BDD7B-1BB5-49F1-AC8A-07E080223B8FQ38524435-4DF48B5B-48EC-4EBE-8D02-2ED591DBA039Q38921141-898BFB81-E54A-4CBD-92AB-4AD6B8CB6DD5Q39441009-16C4315E-C415-4C1F-B2C3-ACBF6F376A78Q39826326-EB877647-9CAE-471E-8025-29EACE73BE2BQ39988673-4D1CA14D-E2F2-46CF-94BF-736B45525476Q40873693-891614B3-FB27-451A-923E-8252DCB50661Q41712924-73F46467-9EFE-445D-8613-59E3803E7EABQ41921898-900C87C7-6D67-4E67-9BE9-E337C7B6712AQ42643753-5AF11FB3-370B-487F-A836-05E331C62C87Q42749584-2B6ACC26-C0DB-41D7-8B79-D3B3D6FDCEE5Q43202927-C8547F62-2635-4104-B0D5-06F5308B1FFE
P2860
Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease.
@ast
Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease.
@en
type
label
Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease.
@ast
Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease.
@en
prefLabel
Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease.
@ast
Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease.
@en
P2093
P2860
P356
P1476
Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease.
@en
P2093
Christian A Schneider
Ele Ferrannini
Erland Erdmann
Guntram Schernthaner
John Yates
Ralph Defronzo
P2860
P304
P356
10.1681/ASN.2007060678
P577
2007-12-05T00:00:00Z